Academician: Battle pancreatic disease to benefit patients, offer 'Oriental Wisdom'
Under the agreement, both parties will thoroughly implement the national strategy for scientific self-reliance, while focusing on key technological challenges in pancreatic diseases, and jointly establishing major research projects that aim to achieve "zero-to-one" breakthroughs.
The parties will also implement the National Health Commission's guidelines on optimizing the layout of grassroots medical institutions, jointly establish projects for grassroots cooperation, and work to widely promote CAP's novel concepts, methods, technologies, and products to grassroots medical institutions nationwide.
Both parties will collaborate on public education programs that raise awareness of pancreatic diseases and foster societal engagement in prevention and treatment efforts.
Representing a groundbreaking initiative in pancreatic disease prevention and treatment, the strategic partnership can help CAP and Hengrui Pharma elevate China's healthcare capabilities in pancreatology, improve public health outcomes, and inject new momentum into the high-quality development of the field.
- 3 workers dead after soil collapse at Guizhou expressway construction site
- Beijing court handles 4,600 online infringement cases involving seniors
- China secures victory against Japan in blind soccer tournament
- Former Heilongjiang vice-governor prosecuted on bribery counts
- Beijing court stresses adult children's responsibility to elderly parents
- Shanghai conservation festival imagines man and nature living harmoniously






























